Elan's Tysabri monotherapy cuts MS progression-journal
MarketWatch - USA
PLC's (ELN) multiple sclerosis drug Tysabri used as a monotherapy cut the risk of disability progression by 42%, according to the results of two phase III ...
See all stories on this topic

Tysabri Studies Suggest MS Efficacy May More than Balance PML Risk
MedPage Today - Little Falls,NJ,USA
AMSTERDAM, March 1 - Although the promising multiple sclerosis drug Tysabri (natalizumab) was pulled from the market in 2005 for safety concerns, an initiative ...

Ireland's Elan shares fall on research report
Reuters - USA
... stock had already been suffering on Tuesday on the back of a US broker report suggesting the use of Elan's suspended multiple sclerosis drug Tysabri might be ...
See all stories on this topic

Elan to suspend trading for two days next week
Ireland Online - Dublin,Ireland
... Exchange (NYSE), will operate during a scheduled US Food and Drug Administration (FDA) advisory committee meeting to review multiple sclerosis drug Tysabri. ...

Three studies of withdrawn MS drug show it's effective, relatively ...
Kansas City Star - MO,USA
The research in Thursday's New England Journal of Medicine comes days before government hearings on whether to allow sales of the drug, Tysabri, to resume. ...

Rituxan OK'd to treat rheumatoid arthritis
USA Today - USA
... An FDA advisory panel is scheduled to meet next week to discuss allowing another Biogen Idec drug, Tysabri, back on the market. ...
See all stories on this topic

Pulled MS drug found safe in two studies
Newsweek - USA
Tysabri, withdrawn last year because of fears it might cause an often-deadly brain disorder, slows the progression of multiple sclerosis and seems to pose ...

German shares up midday, bouncing back from yesterday's sharp ...
Forbes - USA
... 2.28 to 62.60, as news the US Food and Drug Administration is scheduled to meet on March 7 and 8 to decide whether Elan Corp's recalled drug Tysabri -- a rival ...